A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis.
Animals
Antigen-Presenting Cells
Autoantigens
/ genetics
Bystander Effect
/ immunology
Encephalomyelitis, Autoimmune, Experimental
/ therapy
Immunosuppression Therapy
/ methods
Inflammation
/ immunology
Mice
Mice, Inbred C57BL
Multiple Sclerosis
/ therapy
Pseudouridine
/ analogs & derivatives
RNA, Messenger
/ adverse effects
T-Lymphocytes, Regulatory
/ immunology
Vaccines, Synthetic
/ adverse effects
mRNA Vaccines
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
08 01 2021
08 01 2021
Historique:
received:
13
06
2019
revised:
27
04
2020
accepted:
17
11
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
17
2
2021
Statut:
ppublish
Résumé
The ability to control autoreactive T cells without inducing systemic immune suppression is the major goal for treatment of autoimmune diseases. The key challenge is the safe and efficient delivery of pharmaceutically well-defined antigens in a noninflammatory context. Here, we show that systemic delivery of nanoparticle-formulated 1 methylpseudouridine-modified messenger RNA (m1Ψ mRNA) coding for disease-related autoantigens results in antigen presentation on splenic CD11c
Identifiants
pubmed: 33414215
pii: 371/6525/145
doi: 10.1126/science.aay3638
doi:
Substances chimiques
Autoantigens
0
RNA, Messenger
0
Vaccines, Synthetic
0
1-methylpseudouridine
13860-38-3
Pseudouridine
1445-07-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-153Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021, American Association for the Advancement of Science.